Alzheimer's disease

The Alzheimer’s Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.

Barker died at age 99 from Alzheimer’s disease and other contributing factors, as outlined in his death certificate.

August is always an important month for Gales Ferry’s John Clark. The 81-year-old is getting ready for his annual Ride to End Alzheimer’s. This year marks the 25th straight year he has rode his bike with the hopes of raising money to find a cure. “This is a passion for me,” said Clark, who says he has raised about $17,000...

August is always an important month for Gales Ferry’s John Clark. The 81-year-old is getting ready for his annual Ride to End Alzheimer’s.

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.

Researchers say the finger prick would be quick and non-invasive, and samples could be taken at home, then easily transported for testing.

Researchers say the blood test could be taken at home and would indicate changes related to the disease.

If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding.

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.

U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s....

Some people living with Alzheimer’s disease are feeling hopeful about a new medication on the market. It is called Leqembi. However, even though it received accelerated approval from the FDA, it is not covered by the Centers for Medicare and Medicaid Services. Nonetheless, one Connecticut woman managed to get the high-cost medication for her mother. With Mother’s Day this...

Leqembi aims to slow cognitive decline, but costs $26,500 a year and is not covered by insurance.

Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.

The Connecticut Whale welcomes the Toronto Six this weekend for two games in Simsbury. Saturday’s contest is also a game for a cause near to some players’ hearts. It’s their annual Alzheimer’s Awareness Game in partnership with the Alzheimer’s Association of Connecticut. For players like Janine Weber, it’s a game she looks forward to, thinking about how Alzheimer’s has...

A doctor at Yale New Haven Health discusses the Alzheimer’s drug Lecanemab, which the FDA recently granted accelerated approval.

A local family is waiting on a decision from the FDA on whether or not to grant accelerated approval to a drug called Lecanemab. That decision is expected to come Friday. It would impact the Sirois family in Kensington, along with the 6.5 million Americans living with Alzheimer’s Disease. Lecanemab is one of the first experimental drugs to show potential…

The FDA is expected to decide whether or not to grant Lecanemab accelerated approval to fill an unmet medical need.

New data shows an experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening. The next question is how much difference that might make in people’s lives.

Dr. Alison O’Neil is turning skin cells from Alzheimer’s patients into brain cells to study the early markers of the illness and hopefully stop neuron degeneration before it starts.

Assisted Living Services has developed some new services and technology to improve at-home care for people with Alzheimer’s.